{"title":"Dermatofibrosarcoma Protuberans at the Presumed Injection Site following CoronaVac COVID-19 Vaccination: A Case Report.","authors":"Xiaoling Cao, Rong Yin, Dongming Lv, Zhongye Xu, Zhicheng Hu, Bing Tang","doi":"10.1159/000550437","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, locally aggressive cutaneous sarcoma. Trauma and scars have been proposed as potential triggers in a subset of cases.</p><p><strong>Case presentation: </strong>We report a 30-year-old man who developed a progressively enlarging mass in the left deltoid region within several months after receiving two doses of the CoronaVac COVID-19 vaccine administered to the same arm. The lesion was diagnosed as DFSP approximately 19 months after vaccination. Histopathology showed a storiform spindle-cell neoplasm with diffuse CD34 positivity, and fluorescence in situ hybridization demonstrated the COL1A1-PDGFB fusion, consistent with DFSP. The tumor was managed with wide local excision with 2-cm clinical margins; final margins were negative. At 24 months of follow-up after surgery, there was no evidence of local recurrence or metastasis.</p><p><strong>Conclusions: </strong>This case illustrates a temporal association between a new mass at a presumed injection site and DFSP. While causality cannot be inferred from a single case, persistent post-injection nodules should prompt evaluation. The overall benefits of COVID-19 vaccination remain substantial.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"142-147"},"PeriodicalIF":0.7000,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978811/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000550437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, locally aggressive cutaneous sarcoma. Trauma and scars have been proposed as potential triggers in a subset of cases.
Case presentation: We report a 30-year-old man who developed a progressively enlarging mass in the left deltoid region within several months after receiving two doses of the CoronaVac COVID-19 vaccine administered to the same arm. The lesion was diagnosed as DFSP approximately 19 months after vaccination. Histopathology showed a storiform spindle-cell neoplasm with diffuse CD34 positivity, and fluorescence in situ hybridization demonstrated the COL1A1-PDGFB fusion, consistent with DFSP. The tumor was managed with wide local excision with 2-cm clinical margins; final margins were negative. At 24 months of follow-up after surgery, there was no evidence of local recurrence or metastasis.
Conclusions: This case illustrates a temporal association between a new mass at a presumed injection site and DFSP. While causality cannot be inferred from a single case, persistent post-injection nodules should prompt evaluation. The overall benefits of COVID-19 vaccination remain substantial.